Abstract
The Lung Cancer Partnering 2007-2013 provides understanding and access to the
lung cancer partnering deals and agreements entered into by the worlds leading
healthcare companies
The report provides an analysis of lung cancer partnering deals. The majority
of deals are discovery or development stage whereby the licensee obtains a
right or an option right to license the licensors lung cancer technology.
These deals tend to be multicomponent, starting with collaborative R&D, and
commercialization of outcomes.
Understanding the flexibility of a prospective partner's negotiated deals
terms provides critical insight into the negotiation process in terms of what
you can expect to achieve during the negotiation of terms. Whilst many smaller
companies will be seeking details of the payments clauses, the devil is in the
detail in terms of how payments are triggered - contract documents provide
this insight where press releases do not.
This data driven report contains over 200 links to online copies of actual
lung cancer deals and contract documents as submitted to the Securities
Exchange Commission by companies and their partners, where available. Contract
documents provide the answers to numerous questions about a prospective
partner's flexibility on a wide range of important issues, many of which will
have a significant impact on each party's ability to derive value from the
deal.
The initial chapters of this report provide an orientation of lung cancer
partnering trends.
Chapter 1 provides an introduction to the report, whilst chapter 2 provides an
overview of the trends in lung cancer partnering since 2007, including a
summary of deals by industry sector, stage of development, deal type, and
technology type. Numerous tables provide outline financial trends.
Chapter 3 provides an overview of the leading lung cancer deals since 2007.
Deals are listed by headline value, signed by bigpharma, most active
bigpharma. Where the deal has an agreement contract published at the SEC a
link provides online access to the contract.
Chapter 4 provides a comprehensive directory of lung cancer partnering deals
signed and announced since 2007. The chapter is organized by company A-Z,
stage of development at signing, deal type (collaborative R&D, co-promotion,
licensing etc), and technology type. Each deal title links via Weblink to an
online version of the deal record, and where available the contract document,
providing easy access to each contract document on demand.
In conclusion, this report provides everything a prospective dealmaker needs
to know about partnering in the research, development and commercialization of
lung cancer technologies and products.
Report scope
Lung Cancer Partnering 2007-2013 is intended to provide the reader with an
in-depth understanding and access to lung cancer trends and structure of deals
entered into by leading companies worldwide.
This data driven report includes:
- Trends in lung cancer dealmaking in the biopharma industry since 2007
- Access to summary headline, upfront, milestone and royalty data
- The leading lung cancer deals by value since 2007
In Lung Cancer Partnering 2007-2013, the available deals are listed by:
- Headline value
- Upfront payment value
- Royalty rate value
- Company A-Z
- Industry sector
- Stage of development at signing
- Deal component type
- Technology type
Each deal title links via Weblink to an online version of the deal record and
where available, the contract document, providing easy access to each contract
document on demand.
Benefits
Lung Cancer Partnering 2007-2013 provides the reader with the following key
benefits:
- In-depth understanding of lung cancer deal trends since 2007
- Access to summary headline, upfront, milestone and royalty data
- Comprehensive access to over 200 actual lung cancer deals entered into by
the world's biopharma companies since 2007
- Insight into key deal terms included in contracts, where disclosed
- Understand the key deal terms companies have agreed in deals
- Undertake due diligence to assess suitability of your proposed deal terms
for partner companies
About Current Partnering
Current Partnering was established in 2007 and has become the leading publisher of deal term reports within the life sciences. Designed to translate research into commercial success, Current Partnering provides an opportunity for the dissemination of the latest trends in partnering activity across the life sciences.
Current Partnering report titles cover all aspects of partnering best practice and deal terms, providing users with the information and insight required to optimise their partnering activities.
Current Partnering is a trademark of Wildwood Ventures Ltd..
Table of Contents
Executive Summary
Chapter 1 - Introduction
Chapter 2 - Trends in lung cancer partnering
- 2.1. Introduction
- 2.2. Lung cancer partnering over the years
- 2.3. Bigpharma lung cancer dealmaking activity
- 2.4. Lung cancer partnering by deal type
- 2.5. Lung cancer partnering industry sector
- 2.6. Lung cancer partnering by stage of development
- 2.7. Lung cancer partnering by technology type
- 2.8. Disclosed financial deal terms for lung cancer partnering
- 2.8.1. Lung cancer headline values
- 2.8.2. Lung cancer upfront payments
- 2.8.3. Lung cancer milestone payments
- 2.8.4. Lung cancer royalty rates
Chapter 3 - Leading lung cancer deals
- 3.1. Introduction
- 3.2. Top lung cancer deals by value
- 3.3. Top lung cancer deals involving bigpharma
Chapter 4 - Dealmaking directory
- 4.1. Introduction
- 4.2. Company A-Z
- 4.3. By deal type
- Asset purchase
- Bigpharma outlicensing
- Co-development
- Collaborative R&D
- Co-market
- Contract service
- Co-promotion
- CRADA
- Cross-licensing
- Development
- Distribution
- Equity purchase
- Evaluation
- Grant
- Joint venture
- Licensing
- Manufacturing
- Marketing
- Option
- Promotion
- Research
- Settlement
- Spin out
- Sub-license
- Supply
- Termination
- 4.4. By industry sector
- Academic
- Bigpharma
- Biotech
- Drug delivery
- Medical device
- Diagnostic
- Generic pharma
- Government
- Non-profit
- Pharmaceutical
- Research tools
- Services
- Specialty pharma
- 4.5. By stage of development
- Discovery
- Pre-clinical
- Phase I
- Phase II
- Phase III
- Registration
- Marketed
- 4.6. By technology type
- Analysis
- Animal models
- Assays
- Bioinformatics
- Biological compounds
- Biomarkers
- Biomaterials
- Cell culture
- Cell therapy
- Clinical testing
- Diagnostic - companion
- Devices
- Diagnostics
- Discovery tools
- DNA probes
- Drug delivery
- Enabling technology
- Epigenetics
- Equipment
- Facilities
- Gene therapy
- Genomics
- Imaging
- Industrial chemicals
- In vitro models
- Monoclonal antibodies
- Nanotechnology
- Oligonucleotide
- Peptides
- Personalised medicine
- Processes
- Proteomics
- Radio/Chemo-therapy
- Recombinant DNA
- Research services
- Research supplies
- RNA therapeutics
- Screening
- Small molecules
- Stem cells
- Vaccines
Chapter 5 - Partnering resource center
- 5.1. Online partnering
- 5.2. Partnering events
- 5.3. Further reading on dealmaking
Appendices
- Appendix 1 - Deal type definitions
- About Wildwood Ventures
- Current Partnering
- Current Agreements
- Recent titles from CurrentPartnering
- Order Form - Reports
Table of figures
- Figure 1: Lung cancer partnering since 2007
- Figure 2: Bigpharma - top 50 - lung cancer deals 2007 to 2013
- Figure 3: Bigpharma lung cancer deal frequency - 2007 to 2013
- Figure 4: Lung cancer partnering by deal type since 2007
- Figure 5: Lung cancer partnering by industry sector since 2007
- Figure 6: Lung cancer partnering by stage of development since 2007
- Figure 7: Lung cancer partnering by technology type since 2007
- Figure 8: Lung cancer deals with a headline value
- Figure 9: Lung cancer deals with upfront payment values
- Figure 10: Lung cancer deals with milestone payments
- Figure 11: Lung cancer deals with royalty rates, %
- Figure 12: Top lung cancer deals by value since 2007
- Figure 13: Top lung cancer deals signed by bigpharma value since 2007
- Figure 14: Online partnering resources
- Figure 15: Forthcoming partnering events
- Figure 16: Deal type definitions
Lung Cancer Partnering 2007-2013 published by Current Partnering, a division of Wildwood Ventures Limited. This report consists of 250 Pages and the price starts from US $ 1695.
The contents of this page may be different from the latest version. Please contact us for details.
